OXiGENE said that an updated safety and outcome analysis of the Falcon trial has shown that trends towards improved outcomes were observed in response rate, progression-free survival and overall survival rates in the study arm (Zybrestat combined with bevacizumab and carboplatin/paclitaxel chemotherapy) as compared with the control arm (bevacizumab and chemotherapy) of the trial.
OXiGENE said that the combination regimen including Zybrestat was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study. OXiGENE expects that further data from the trial will be available later in 2010.
Peter Langecker, CEO of OXiGENE, said: “We continue to be encouraged by the growing body of data showing that Zybrestat has potential as an important cancer treatment based on its unique vascular disrupting mechanism of action and excellent combinability with other treatment modalities, including anti-angiogenic agents.
“We look forward to presenting a more complete analysis of the Falcon trial later in 2010 at a scientific meeting. If the encouraging positive trends in terms of progression free survival and overall survival that we presented at ASCO are maintained, they will underscore Zybrestat ‘s utility in non-small cell lung cancer and potentially pave the way toward embarking upon a registration pathway. We appreciate the positive response to our data from the oncology community and plan to continue efforts to find a partner for later-stage development.”